GEVO, INC.

GEVO, INC. specializes in scientific research and development services, primarily focused on advanced biochemical and biotechnological innovation. Their core capabilities center on process development, fermentation optimization, and sustainable chemical synthesis, with technical expertise in metabolic engineering, biocatalysis, and life cycle analysis for renewable product platforms. The company applies systems biology and synthetic biology methodologies to design and scale bio-based alternatives to petroleum-derived chemicals, emphasizing carbon efficiency and industrial scalability. Key differentiators include proprietary strain development platforms and integrated pilot-scale validation capabilities that bridge laboratory discovery with commercial deployment. Their work is grounded in rigorous analytical validation, process control systems, and regulatory alignment for industrial biotechnology applications. Award history does not provide sufficient detail to identify specific federal agencies or programmatic relationships. Consequently, no definitive patterns of engagement with government entities can be inferred from available data. The primary NAICS code 541714 reflects a focus on research and development in biotechnology, encompassing applied science activities that translate biological systems into industrial solutions. In practice, this means GEVO operates at the intersection of biochemistry, chemical engineering, and environmental sustainability, serving markets that require renewable feedstocks, low-carbon manufacturing, and bio-based material substitution. Their market positioning is that of a niche R&D innovator in the industrial biotechnology sector, with an emphasis on scalable bio-processes rather than diagnostic or therapeutic applications. GEVO, INC. is structured as a small business (2L entity) headquartered in Englewood, Colorado. The company holds no government certifications, and its geographic footprint is limited to its primary operational base. While it maintains a focused technical presence in the federal R&D ecosystem, its government market positioning cannot be characterized due to insufficient award data to infer programmatic alignment or procurement relationships.